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n recent years, highly pathogenic 
avian inﬂ  uenza A viruses of the 
H5N1 subtype have crossed the 
species barrier and infected humans in 
many parts of the world. These strains 
continue to evolve and expand their 
host range, and have been associated 
with greater than 50 percent mortality 
[1]. No vaccines directed against H5N1 
strains are commercially available 
for humans, and the development 
of effective H5N1 vaccines poses a 
number of challenges on both the basic 
science and manufacturing levels [2]. 
    Several strategies have been 
explored to produce effective H5 
vaccines. These include: preparation 
of an inactivated vaccine using a 
heterotypic (see Glossary), low-
pathogenicity avian inﬂ  uenza virus 
that is antigenically related to the 
H5N1 circulating strains [3]; use of 
a recombinant H5 hemagglutinin 
(HA) expressed in baculovirus [4]; an 
inactivated subvirion vaccine [5]; or the 
production of attenuated seed viruses 
with the H5 HA modiﬁ  ed through 
reverse genetics [6–8]. Unfortunately, 
many of these approaches have been 
found to be poorly immunogenic, 
require high doses of antigen, or 
require the use of an adjuvant 
[1,9]. An alternative approach 
under development is the use of live 
attenuated cold-adapted H5 vaccines.
    Live attenuated cold-adapted 
vaccines are attractive for the 
prevention of pandemic inﬂ  uenza 
due to the stimulation of an immune 
response following a single dose of 
vaccine, an excellent safety proﬁ  le, 
induction of cross-reactive immune 
responses, and efﬁ  cacy in children 
[10]. Although the cold-adapted virus is 
live, it does not replicate to high titers 
and fails to readily infect naïve people 
[11]. Through the use of reverse 
genetics, a cold-adapted H9 inﬂ  uenza 
virus–speciﬁ  c seed virus has already 
been produced and is available for 
clinical evaluation and use should the 
need arise [12]. A new study in   PLoS 
Medicine   now describes the generation 
of live, attenuated H5N1 inﬂ  uenza 
viruses that may be suitable candidates 
for use in humans [13].
  The  New  Study 
    In the current work, the authors 
used reverse genetics to construct 
high-yield 6:2 seed viruses by mixing 
the six internal genes from a cold-
adapted   (ca)   donor virus with the H5 
HA and N1 neuraminidase (NA) from 
representative H5N1 inﬂ  uenza strains. 
An important safety feature used in 
these studies was the modiﬁ  cation of 
the multi-basic amino acid motif at 
the cleavage site of the H5 HA gene 
to a sequence seen in avian inﬂ  uenza 
viruses that are not highly pathogenic 
in chickens [6]. This alteration 
affords several advantages, including 
attenuated growth in embryonated 
eggs, allowing high yields to be 
attained, and increased safety due to 
restricted replication of the virus in 
the host [2]. The H5N1 ca viruses were 
attenuated in vivo in mice, ferrets, 
and chickens as compared to the 
H5N1 wild-type   (wt)   viruses. The level 
of replication of the H5N1   ca   viruses 
was decreased in the respiratory tract 
of mice and ferrets as compared to 
  wt   viruses, and systemic spread was 
abrogated. The poor infectivity of the 
H5N1   ca   viruses in chickens suggests 
that, if used during a pandemic, 
the H5N1   ca   viruses would pose 
no risk to the poultry industry, an 
important economic and public health 
consideration.
    To evaluate the immunogenicity of 
the H5N1   ca   vaccine candidates, each 
of the viruses was administered to mice 
and ferrets, and antibody responses 
were monitored. A single dose of 
vaccine was poorly immunogenic 
in mice, generating low antibody 
responses. However, it fully protected 
from lethal challenge with homologous 
H5N1   wt   viruses, lowered viral titers 
in the respiratory tract, and prevented 
systemic spread of the   wt   viruses to the 
brain. Most excitingly, this single dose 
provided complete protection from 
lethal challenge with H5N1 viruses 
from representative viruses from 
diverse clades, including the newly 
isolated 2005 viruses. Administration of 
a second, boosting dose of the vaccine 
elicited higher antibody titers with 
greater cross-reactive responses and 
afforded near complete protection 
against not only mortality but viral 
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replication of both homologous 
and heterologous strains. Two doses 
of the H5N1   ca   vaccine candidates 
also completely protected ferrets 
from viral replication in the lungs 
following homologous or heterologous 
challenge, including challenge with 
107 50% tissue culture infectious dose 
(TCID50) of A/Indonesia/5/2005 
(H5N1).
    Importance of the Study
    Live, attenuated inﬂ  uenza virus 
vaccines have been approved for use 
in healthy persons ﬁ  ve to 49 years of 
age and have been shown to be highly 
efﬁ  cacious against inﬂ  uenza-associated 
lower respiratory tract disease and 
otitis media in children [11]. They 
also have signiﬁ  cant advantages over 
inactivated vaccines for immunizing 
naïve populations, including induction 
of higher and more durable levels of 
antibody and generation of cellular 
and mucosal immunity. This combined 
humoral, mucosal, and cellular 
immune response may result in broad 
protection against antigenically drifted 
strains, an important advantage since 
we do not know what future strain will 
become established in humans and 
cause the next pandemic. Because 
prior immunity to the HA of strains 
contained in the vaccine may limit viral 
replication and therefore induction of 
immunity, this approach may actually 
work better in persons naïve to the 
virus as is required by deﬁ  nition for 
a vaccine strain to achieve pandemic 
status. 
    The studies by Suguitan et al. 
provide clinicians with a powerful tool 
in the ﬁ  ght against pandemic H5N1 
inﬂ  uenza viruses: an “off-the-shelf” 
seed virus that could be standardized, 
rapidly produced, and safely handled 
by vaccine manufacturers for vaccine 
production against a diverse population 
of H5N1 viruses. The production of 
H5N1 live attenuated viruses with 
modiﬁ  cations to the multi-basic 
cleavage site also provide assurance 
that these viruses, if shed into the 
environment, would pose limited risk to 
the poultry industry and potentially to 
public health. Although a single dose 
of vaccine did not induce complete 
protection from viral replication in the 
animal model, in the clinical setting 
this partial protection may translate 
to protection from severe illness and 
death in humans. 
  Implications  and  Limitations 
of the Approach
    In the event of an H5N1 pandemic, will 
we be prepared? That question looms 
on the minds of clinicians, researchers, 
and policy makers worldwide. The 
approach presented here by Suguitan 
et al. may represent an important 
advance in generating effective H5N1 
vaccines. However, two potential 
caveats remain. 
    First, the immunogenicity of live, 
attenuated viruses bearing an H5 
HA must be established in humans. 
Other vaccine approaches have 
protected mice against H5N1 viruses 
but proved poorly immunogenic in 
humans. However, the efﬁ  cacy of 
this vaccine candidate in ferrets is an 
important indicator of its potential 
utility in humans. Second, the risk of 
reassortment of the vaccine virus with 
a wild-type human inﬂ  uenza virus 
must be considered. Although live, 
attenuated inﬂ  uenza viruses do not 
transmit well, reassortment within a 
person vaccinated and then coinfected 
with wild-type inﬂ  uenza virus could 
result in a hybrid virus fully competent 
for replication and transmission in 
humans that contains the antigenically 
novel H5 HA, inadvertently triggering 
a pandemic. This concern will limit 
clinical testing of the vaccine in 
humans and may restrict use of this 
vaccine approach to the period after 
a new pandemic strain has begun 
to circulate. Nonetheless, the work 
from Suguitan et al. is an important 
step along the path to inﬂ  uenza 
preparedness and warrants further 
development.   
 Glossary
   Baculovirus:  A particular virus infecting 
insects or insect cells. Commonly used for 
production of recombinant proteins.
   Cold-adapted  vaccine:  A virus modiﬁ  ed 
to replicate efﬁ  ciently only at lower 
temperatures, resulting in attenuated 
growth limited to the upper respiratory 
tract.
   Heterotypic:  Of a different type or form.
   High-yield  6:2  seed  virus:  A viral stock 
containing six viral genes from one strain 
and two viral genes (typically HA and NA) 
from the strain of interest.
   Reverse  genetics:  Cutting-edge 
molecular technology used to create 
inﬂ  uenza viruses from plasmids.
   Seed  virus:  A virus used as a “stock” for 
vaccine production. 
  References
    1.  Beigel JH, Farrar J, Han AM, Hayden FG, Hyer 
R, et al. (2005) Avian inﬂ  uenza A (H5N1) 
infection in humans. N Engl J Med 353: 1374–
1385.
    2.  Palese P (2006) Making better inﬂ  uenza virus 
vaccines? Emerg Infect Dis 12: 61–65.
    3.  Nicholson KG, Colegate AE, Podda A, 
Stephenson I, Wood J, et al. (2001) Safety and 
antigenicity of non-adjuvanted and MF59-
adjuvanted inﬂ  uenza A/Duck/Singapore/97 
(H5N3) vaccine: A randomised trial of two 
potential vaccines against H5N1 inﬂ  uenza. 
Lancet 357: 1937–1943.
    4.  Treanor JJ, Wilkinson BE, Masseoud F, Hu-
Primmer J, Battaglia R, et al. (2001) Safety 
and immunogenicity of a recombinant 
hemagglutinin vaccine for H5 inﬂ  uenza in 
humans. Vaccine 19: 1732–1737.
    5.  Treanor JJ, Campbell JD, Zangwill KM, Rowe 
T, Wolff M (2006) Safety and immunogenicity 
of an inactivated subvirion inﬂ  uenza A (H5N1) 
vaccine. N Engl J Med 354: 1343–1351.
    6.  Li S, Liu C, Klimov A, Subbarao K, Perdue ML, 
et al. (1999) Recombinant inﬂ  uenza A virus 
vaccines for the pathogenic human A/Hong 
Kong/97 (H5N1) viruses. J Infect Dis 179: 
1132–1138.
    7.  Subbarao K, Chen H, Swayne D, Mingay 
L, Fodor E, et al. (2003) Evaluation of a 
genetically modiﬁ  ed reassortant H5N1 
inﬂ  uenza A virus vaccine candidate generated 
by plasmid-based reverse genetics. Virology 
305: 192–200.
    8.  Webby RJ, Perez DR, Coleman JS, Guan Y, 
Knight JH, et al. (2004) Responsiveness to a 
pandemic alert: Use of reverse genetics for 
rapid development of inﬂ  uenza vaccines. 
Lancet 363: 1099–1103.
    9.  Wong SS, Yuen KY (2006) Avian inﬂ  uenza virus 
infections in humans. Chest 129: 156–168.
    10. Belshe RB, Gruber WC (2001) Safety, efﬁ  cacy 
and effectiveness of cold-adapted, live, 
attenuated, trivalent, intranasal inﬂ  uenza 
vaccine in adults and children. Philos Trans R 
Soc Lond B Biol Sci 356: 1947–1951.
    11. Murphy BR, Coelingh K (2002) Principles 
underlying the development and use of live 
attenuated cold-adapted inﬂ  uenza A and B 
virus vaccines. Viral Immunol 15: 295–323.
    12. Chen H, Matsuoka Y, Swayne D, Chen 
Q, Cox NJ, et al. (2003) Generation and 
characterization of a cold-adapted inﬂ  uenza A 
H9N2 reassortant as a live pandemic inﬂ  uenza 
virus vaccine candidate. Vaccine 21: 4430–4436.
    13. Suguitan AL Jr., McAuliffe J, Mills KL, Jin 
H, Duke G, et al. (2006) Live, attenuated 
inﬂ  uenza A H5N1 candidate vaccines provide 
broad cross-protection in mice and ferrets. 
PLoS Med 3: e360. DOI: 10.1371/journal.
pmed.0030360 
September 2006  |  Volume 3  |  Issue 9  |  e375